Oncimmune Holdings Plc engages in diagnosing cancer. It is involved in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. The company's operating segment includes Early CDT Lung and ImmunoINSIGHTS. The company was founded in 2002 and is headquartered in Nottinghamshire, the United Kingdom.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company